Daré Bioscience Completes Regulation A Preferred Stock Offering

Daré Bioscience ( (DARE) ) has shared an announcement.

On April 10, 2026, Daré Bioscience completed a closing of its previously announced Regulation A offering of Investor Units, each consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock, priced at $5.00 per unit. In this closing, the company issued 3,470 Investor Units, comprising 3,470 shares of Series A Preferred Stock and Investor Warrants to purchase up to 6,940 shares of common stock, providing additional capital that may support its operations and strategic initiatives in the women’s health market.

The most recent analyst rating on (DARE) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Daré Bioscience stock, see the DARE Stock Forecast page.

Spark’s Take on DARE Stock

According to Spark, TipRanks’ AI Analyst, DARE is a Neutral.

The score is primarily held down by weak financial performance characterized by large losses, heavy cash burn, and balance-sheet instability. Offsetting factors include improving near-term technical positioning and a constructive earnings-call outlook with upcoming launches and grant-supported programs, while valuation remains challenged due to negative earnings and recent financing adds some funding support but with dilution risk.

To see Spark’s full report on DARE stock, click here.

More about Daré Bioscience

Daré Bioscience, Inc. is a biopharmaceutical company focused on developing and commercializing products in the women’s health sector. Its primary activities center on advancing innovative therapeutics and technologies targeting unmet needs in reproductive and sexual health, positioning the company within a specialized niche of the life sciences industry.

Average Trading Volume: 86,608

Technical Sentiment Signal: Sell

Current Market Cap: $26.64M

Find detailed analytics on DARE stock on TipRanks’ Stock Analysis page.